Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 9 - 12 February 2026
Referral: Levamisole-containing medicinal products, levamisole, associated names: Decaris,Levamisol Arena Article 31 referrals Recommendation provided by Pharmacovigilance Risk Assessment Committee, 13/02/2026
EMA recommends withdrawal of marketing authorisations for levamisole medicines
Medicine shortage communication (MSC): Natpar (parathyroid hormone) (25, 50, 75 and 100 micrograms/dose powder and solvent for solution for injection)
Clinical investigation of medicinal products in the treatment of Myasthenia Gravis
Concept paper on the need of a guideline on clinical investigation of medicinal products in the treatment of Myasthenia Gravis
Paediatric investigation plans: questions and answers
Review of the stepwise paediatric investigation plan (sPIP) pilot: Outcomes and future perspectives
Paediatric investigation plans
Human medicines European public assessment report (EPAR): Vantavo (previously Alendronate sodium and colecalciferol, MSD), alendronic acid,colecalciferol, Date of authorisation: 16/10/2009, Revision: 22, Status: Authorised